HC Wainwright also issued estimates for Dogwood Therapeutics’ Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.58) EPS, Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($3.14) EPS, FY2028 earnings at ($3.29) EPS and FY2029 earnings at $1.12 EPS. Dogwood Therapeutics Price PerformanceInstitutional Trading of Dogwood TherapeuticsShares of DWTX opened at $6.42 on Thursday. An institutional investor recently bought a new position in Dogwood Therapeutics stock. FNY Investment Advisers LLC owned 0.65% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. Dogwood Therapeutics Company Profile(Get Free Report)Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness.